Log in
Nephrology

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people

NEOCYST/IPNA/ESPN2019Full text
Full text · CC BYGimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M et al.. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol, 2019. Licensed under CC BY. Changes: reformatted for the web. Original: https://doi.org/10.1038/s41581-019-0155-2

Summary

These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology, human genetics, paediatric radiology and ethics specialties together with patient representatives. They have been endorsed by the International Pediatric Nephrology Association (IPNA) and the European Society of Paediatric Nephrology (ESPN). For asymptomatic minors at risk of ADPKD, ongoing surveillance (repeated screening for treatable disease manifestations without diagnostic testing) or immediate diagnostic screening are equally valid clinical approaches. Ultrasonography is the current radiological method of choice for screening. Sonographic detection of one or more cysts in an at-risk child is highly suggestive of ADPKD, but a negative scan cannot rule out ADPKD in childhood. Genetic testing is recommended for infants with very-early-onset symptomatic disease and for children with a negative family history and progressive disease. Children with a positive family history and either confirmed or unknown disease status should be monitored for hypertension (preferably by ambulatory blood pressure monitoring) and albuminuria. Currently, vasopressin antagonists should not be offered routinely but off-label use can be considered in selected children. No consensus was reached on the use of statins, but mTOR inhibitors and somatostatin analogues are not recommended. Children with ADPKD should be strongly encouraged to achieve the low dietary salt intake that is recommended for all children.

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disease in adults, with an estimated prevalence of 1 in 500–2,500 (refs1–4). Cyst development starts early in life, and macroscopic cysts can become detectable in childhood. Substantial disease burden with massively enlarged kidneys or decreased glomerular filtration rate (GFR) usually does not occur until adulthood5; however, approximately 3% of children who carry ADPKD-causing mutations have either very-early-onset or unusually rapid progressive disease5–7. Thus, the absolute incidence of symptomatic ADPKD in childhood is thought to be higher than that of other severe paediatric kidney diseases such as autosomal recessive polycystic kidney disease (~1 in 20,000), nephrotic syndrome (~1 in 50,000)8 or haemolytic uraemic syndrome (~1 in 100,000 children)9.

The past 25 years have seen remarkable progress in knowledge of ADPKD. Advances have been made in unravelling the genetic origins of the disease, in non-invasive monitoring and in predicting disease progression; multiple large-scale clinical trials have been conducted; and the first pharmacological treatment for slowing disease progression — the vasopressin antagonist tolvaptan — has been licensed in the USA, Europe and Japan10. However, most ADPKD studies have been performed in adults, and their results are not always easily transferable to children.

Children with ADPKD constitute a mixed cohort of healthy individuals who may not require treatment for decades (referred to here as asymptomatic patients) and individuals who have disease manifestations, such as hypertension, and will benefit from treatment started as early as possible. Few children suffer from symptomatic disease manifestations such as pain, enuresis, haematuria or urinary tract or cyst infections. Both symptomatic and asymptomatic children are likely to be confronted with the effects of ADPKD in older relatives and to have questions or anxieties about their own future health. In addition, many children with an affected parent are unaware of their own disease status (referred to here as at-risk children), either because diagnostic testing has not been performed or because a negative ultrasonography scan does not exclude ADPKD in childhood. An important dilemma in the medical care of children with ADPKD is the balance between not medicalizing currently healthy individuals and not missing treatable disease manifestations in those affected at an early age. Medical professionals from different backgrounds, nurses, affected parents and at-risk children naturally have different views on where this balance lies.

The objective of this Consensus Statement is to provide clinical guidance on counselling, diagnosing and monitoring children with ADPKD in light of the current evidence and a multi-stakeholder discussion of ethical issues surrounding early diagnosis and monitoring.

Methods

The consensus process was initiated by the Network for Early Onset Cystic Kidney Disease (NEOCYST), which is a consortium of clinical, genetic and translational researchers devoted to the study of early-onset cystic kidney diseases11. In addition to paediatric nephrologists from the consortium, external experts in paediatric ADPKD, adult ADPKD, cystic kidney disease genetics, paediatric radiology and patient representatives were invited to participate (Supplementary information). C.G., M.C., R.D.P., R.T., J.K., M.D.S., J.K., A.M.M., A.T. and D.M. prepared systematic literature reviews in advance of the consensus conference held on 1 December 2017 in Leuven, Belgium. Tabulated results of the literature reviews are included in the Supplementary information.

Initial recommendations were developed during the conference by discussion in thematic workgroups and plenary sessions. Evidence and recommendations were graded according to the method used in the current American Academy of Pediatrics (AAP) guidelines12,13 (Fig. 1). The grading of recommendations into strong, moderate and weak recommendations takes into account not only the quality of the evidence but also the balance of potential benefits and harms assessed by the consensus group12. The preliminary results of the consensus meeting were presented on 2 December 2017 at an international symposium on ‘Management of Polycystic Kidney Diseases from Childhood to Adulthood’ in Leuven, Belgium, where 104 participants voted live and anonymously on the major drafted recommendations. A first written draft was compiled by C.G. and reviewed by all members of the consensus group. Consequently, two rounds of anonymous voting were performed using the Delphi method until each recommendation reached at least 70% support. The results of the symposium votes and the Delphi votes are presented in the Supplementary information.

Fig. 1 Matrix used for grading of evidence and assigning strength of recommendations.

This matrix is currently used by the American Academy of Pediatrics12,13. Reproduced with permission from ref.13: Pediatrics 140, e20171904 Copyright © 2017 by the AAP.

— figure not reproduced here; see the original article.

The final draft of the Consensus Statement was endorsed by the council of the International Pediatric Nephrology Association (IPNA) and the European Society of Paediatric Nephrology (ESPN) after thorough review by members of the ESPN Workgroup for inherited kidney diseases. The manuscript was also reviewed by ADPKD experts from the European Rare Kidney Disease Reference Network (ERKNet), whose helpful comments were incorporated. Suggestions for further research are listed in the Supplementary information.

Screening in at-risk minors

The question of whether to screen at-risk children of parents affected by ADPKD is a regularly encountered but often contentious clinical issue14. Both genetic testing and ultrasonography screening should be considered diagnostic and require prior counselling (Box 1).

Counselling

Uncertainty about a child’s disease status causes a high psychological burden for many families15. Parents of at-risk children should be informed about the possibilities, limits and consequences of genetic and clinical testing of their children by appropriately skilled personnel. They should understand that screening examinations do not always yield definitive results and importantly that a normal kidney ultrasonography scan has a low negative predictive value in children. Offering diagnostic screening does not imply that this screening is advised but provides parents with the opportunity to make an informed choice. As time for non-directional genetic counselling may be limited in general practice and adult nephrological care, referral to a geneticist or specialized ADPKD clinic may be required. In the case of a child being presented to a paediatric nephrology clinic for testing, adequate parental understanding of the ethical issues should be confirmed before screening. Reliable external information, such as patient support groups, can also help in decision-making.

An important argument against diagnostic testing for ADPKD in childhood is respecting the autonomy of the children or young adults to decide whether to undergo testing for a genetic disease for which a diagnosis might not have therapeutic consequences until adulthood. Treatments to slow disease progression in children with ADPKD are limited, and no clear evidence exists to suggest that presymptomatic detection improves outcomes16. In addition, establishing a clinical or genetic diagnosis may have a substantial impact on the future ability of the child to secure insurance policies or to gain access to certain professions. Considerations about insurance vary substantially by place of residence; in some countries, the results of genetic screening tests can legally be kept confidential, whereas in others a positive family history alone will affect insurability.

On the other hand, both the American and the European Society of Human Genetics consider presymptomatic testing of minors for conditions with adult-onset acceptable if preventive actions can be initiated before adulthood17,18. Cohort studies in children with ADPKD show an elevated incidence of hypertension, proteinuria and left ventricular hypertrophy, which affect prognosis and are amenable to treatment19. Although these data are from tertiary referral centre populations and thus may be biased towards more severe cases, they demonstrate that a subgroup of children exists in whom preventive treatment may be beneficial. Another potential advantage of early diagnosis is that the teenage years can provide a valuable opportunity to integrate lifestyle interventions such as a healthy, low-salt diet and adequate fluid intake into the development of eating habits (discussed further below). The advent of treatment to slow disease progression and of pre-implantation genetic diagnosis have persuaded some clinicians to advocate screening for young adults20. For children, the situation is less clear as pharmacological studies in paediatric patients are ongoing and safe treatment options for children with acceptable adverse effects and proven benefits have not yet been established.

Immediate or delayed screening

In our view, parents and young people may reasonably opt for either immediate diagnostic testing to confirm disease status or regular clinical screening to identify disease manifestations with the option of later diagnostic testing. Regular clinical screening mainly comprises measurement of blood pressure and proteinuria, which should be performed at the same intervals as those recommended for children with proven symptomatic or asymptomatic disease (see below). The feasibility of regular blood pressure monitoring in the community may vary in different settings and should be taken into account.

We recommend that parents receive non-directional counselling about the potential benefits and uncertainties of current diagnostic screening tests. Health-care professionals should inform parents with the aim of shared decision-making and encourage them to keep the best interests of the child in mind. Teenagers and competent younger children should be involved in the decision-making process as much as possible, and ideally a family approach will facilitate discussion to balance the views of the parents and the young person. We also encourage talking to children and adolescents about the possibility of disease transmission early on in an age-appropriate way as this positively influences coping and family interactions21–23. If discussion with the child is deferred until the formal age of majority, families may benefit from the help of a genetic counselling service or a similarly trained professional22.

Radiological diagnosis

Renal ultrasonography

The current gold standard for radiological diagnosis of ADPKD is renal ultrasonography (Box 2). Ultrasonography is an inexpensive and non-invasive method of examination that is particularly suitable for children because of their smaller body size and the fact that the procedure does not require sedation or ionizing radiation. Diagnostic ultrasonography criteria for ADPKD have been established only for adults24; however, in children, there is usually no clinical need to make a genetic diagnosis regardless of the ultrasonography findings or to perform more sensitive diagnosis using MRI (which may require sedation) if the renal ultrasonography scan is normal as cyst burden correlates with the risk of the main complications such as hypertension25. In line with clinical practice guidelines for adults26–28, we recommend reserving genetic testing to selected situations (see below). We have provided detailed guidance on the prenatal and postnatal imaging of single and multiple kidney cysts and their differential diagnosis in separate statements29,30.

Diagnostic specificity and sensitivity

In a PKD1 gene linkage analysis study, the diagnostic specificity of one or more cysts on ultrasonography in at-risk children was 89% in those younger than 5 years of age and 100% in those older than 5 years of age31. Failure to confirm cysts on follow-up has been reported rarely with single but not with multiple cysts32–34 and may be due, for example, to a mistaken dilated calyx, mistaken prominent medullary pyramid or technical difficulties in obese children. For young adults, established imaging diagnostic criteria require at least three renal cysts on ultrasonography24,35 or ten on MRI36. However, the studies on which these criteria are based did not include patients younger than 15 years of age. Numerous studies have shown that, owing to the gradual appearance of cysts, children with ADPKD usually have a much lower number of cysts than adults, and young children may not yet have detectable cysts on ultrasonography, especially in families with a mild phenotype31–34,37–42. Diagnostic sensitivity is therefore better in older than in younger children and with the use of high-resolution versus lower-resolution ultrasonography. Parents should be counselled that the negative predictive value of a normal ultrasonography scan in childhood is limited and that later appearance of cysts may be due to a milder underlying genetic alteration (for example, PKD2 or GANAB (glucosidase-α neutral AB form) mutations) or variability of the individual clinical course37. As cysts develop slowly and children with fewer cysts have later onset of hypertension and proteinuria25,43–45, children with a normal ultrasonography scan should not be subjected to frequent repeat scans.

Multiple cysts

The incidence of simple cysts in children is very low46. Multiple kidney cysts in childhood are therefore highly suggestive of ADPKD or another cystic nephropathy (such as cystic dysplasia or multicystic-dysplastic kidney) and should be investigated. Clinical work-up will include inquiry about (related) symptoms, detailed history and physical examination and may require further investigations of other organ systems. Parental examination may reveal previously undetected ADPKD47.

Solitary cysts

In children with a positive family history, a solitary cyst is a very likely sign of ADPKD, but in rare cases the cyst may not be confirmed on follow-up32–34. In children with a negative family history, ultrasonography of the parents should be performed and, if the results are normal, further work-up or follow-up of the child is needed to exclude the appearance of multiple cysts or the development of a complex cyst.

MRI

In adults and probably also teenage children, MRI is more sensitive than ultrasonography for detection of kidney cysts in ADPKD36,43,48. In neonates and infants, high-resolution ultrasonography can detect even small cysts, but no studies have defined a gold standard for imaging kidney cysts in this age group. As MRI usually requires sedation in children younger than 6 years and is more expensive than ultrasonography imaging, it is not the diagnostic method of choice for paediatric ADPKD.

Molecular diagnosis

In adults, genetic testing for ADPKD is usually not done because of the clearly established imaging diagnostic criteria and the technical challenges of sequencing PKD1. However, knowledge about genotype–phenotype correlations is increasing, as is the need for more accurate estimation of prognosis in view of novel therapies49.

Both very-early-onset ADPKD and rapidly progressive disease may be due to unusual genetic constellations, such as biallelic mutations (homozygous, compound heterozygous or digenic) with at least one weak PKD1 or PKD2 hypomorphic allele5,50–52. Combinations of an ADPKD allele with an allele of another cystic nephropathy such as TSC2 (for example, as a contiguous gene deletion syndrome (CGS)) may also radically alter the renal disease phenotype53. HNF1B mutations can mimic ADPKD with important consequences for prognosis, the likelihood of comorbidities (for example, congenital hepatic fibrosis in PKHD1 or maturity onset diabetes of the young type 5 (MODY5) in HNF1B) and the risk of disease in siblings54. Where available, simultaneous analysis of a panel of polycystic kidney disease genes is recommended for children with very-early-onset disease independent of their family history or rapidly progressive cystic kidney disease and negative family history (Box 3). An unusually severe clinical course with a positive family history may also be a sign of an unusual genetic constellation, but the likelihood is much lower than in the aforementioned cases. Patients with incidental finding of a single cyst and no extrarenal features should primarily receive clinical work-up and be followed up by imaging. Genetic testing is unlikely to reveal a monogenic cause or change management.

We currently recommend next-generation sequencing panel examination rather than testing single ADPKD genes because of the large phenotypic overlap between different cystic kidney diseases and large genetic heterogeneity54. A cystic kidney disease panel should include adequate coverage of PKD1, PKD2, PKHD1, Daz-interacting zinc-finger protein 1-like (DZIP1L), HNF1B and genes for other ciliopathies such as nephronophthisis (NPHP) and Bardet–Biedl syndrome (BBS).

Hypertension

Hypertension is one of the most common complications of ADPKD in childhood. A systematic review by Marlais et al. that included >900 children with ADPKD from 14 studies reported that the prevalence of hypertension was 20% (95% CI 15–27%); this prevalence was shown to increase with age in a meta-regression analysis19. This finding might be influenced by tertiary centre referral bias because the clinical experience with adult patients suggests that hypertension frequently becomes apparent later in life. The average age of onset of hypertension in adults with ADPKD is 30–34 years55 and precedes loss of renal function. A study from large centres that included children and adults confirmed a risk of hypertension of approximately 20% for those younger than 19 years of age, which is significantly higher than that of this age group in the healthy population (<2%)56. Elevated blood pressure is significantly associated with kidney volume and cyst score in children with ADPKD25,43–45,57.

Blood pressure measurement

As hypertension is the main treatable disease manifestation of ADPKD in childhood, we recommend adhering to the stringent yearly monitoring intervals for clinic blood pressure measurements recommended by the AAP and the European Society of Hypertension (ESH) for otherwise healthy children13 (Box 4). This recommendation also applies to at-risk children of affected parents who have chosen to defer diagnostic testing.

Ambulatory blood pressure monitoring (ABPM) is more reproducible and accurate than clinic blood pressure measurement58, and ABPM values associate more closely with left ventricular hypertrophy in children59 and with renal disease progression or death in adults with chronic kidney disease (CKD)60 than do clinic blood pressure values. A substantial proportion of children with CKD have masked hypertension61, justifying the routine use of ABPM for high-risk children13. In addition, ABPM can exclude white coat hypertension and help to avoid unnecessary treatment62. ABPM becomes more useful as children age because measurements are less well tolerated by younger children, who also have a lower prevalence of hypertension19, and reliable reference values are available only for individuals with a height of ≥120 cm. Isolated night-time hypertension with normal daytime blood pressure, which can be picked up only on ABPM, has been reported in 16–18% of children with ADPKD25,57. This finding underlines the usefulness of ABPM in this patient group. Monitoring intervals will depend on local availability, level of clinic blood pressure and/or the use of antihypertensive medication.

Home blood pressure measurements are less suitable than repeated clinic or ABPMs for initial diagnosis of hypertension owing to the current lack of definitive paediatric reference values13. However, home measurements can be useful to assess changes over time, monitor treatment and increase compliance, thus helping to reduce the frequency of more costly ABPM63,64. The use of home blood pressure measurement will depend on the compliance of the family and the child, as well as the availability of monitors that have been specifically validated for children.

Antihypertensive treatment

Blood pressure thresholds

No studies on blood pressure thresholds for antihypertensive treatment in paediatric hypertension have been published. Owing to the high cardiovascular mortality of patients with childhood-onset CKD65 and the beneficial effect of lowering blood pressure on progression of renal disease66, we support the low antihypertensive treatment threshold (ninetieth percentile for age, sex and height, which equals 130/85 mmHg on clinic measurements for those ≥16 years of age) that is recommended for children with CKD by Kidney Disease: Improving Global Outcomes (KDIGO)67.

Blood pressure targets

A randomized controlled trial (RCT) of antihypertensive therapy in children with CKD stage 2–4 showed a significant beneficial effect on renal survival when treatment was targeted to reduce 24-hour mean arterial pressure to below the fiftieth percentile on ABPM66. However, a post hoc analysis reported no further benefit for an achieved blood pressure below the seventy-fifth percentile66. The HALT-PKD Study A demonstrated a significant benefit of a lower blood pressure goal (95/60 to 110/75 mmHg) versus a standard blood pressure target (120/70 to 130/80 mmHg) in terms of total kidney volume (TKV), left ventricular mass index (LVMI) and albuminuria in adults with ADPKD and stage 1–2 CKD68. However, a smaller randomized trial of intensive blood pressure control in children with ADPKD did not reach statistical significance69. Thus, the long-term benefits of lower blood pressure need to be balanced against the need for more medications and higher risk of adverse effects in the short term. We consider the KDIGO and ESH blood pressure target for children with CKD (less than the seventy-fifth percentile) to be more evidence-based for use in children with ADPKD than the stricter AAP target (less than the fiftieth percentile).

First-line treatment

Compared with other antihypertensive agents, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have the largest evidence base for efficacy and safety in paediatric patients and in patients with renal hypertension. In patients with proteinuria, the superiority of ACE inhibitors and ARBs over other antihypertensive drug classes has been clearly demonstrated70. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors have superior efficacy to β-blockers or calcium channel blockers in adults with ADPKD is less clear71–74. Dual RAAS blockade does not seem to have additional benefit on disease progression over that of improved blood pressure control compared with an ACE inhibitor or ARB alone in adults with early or late ADPKD68,75. Diuretics should be used with caution as they may increase vasopressin levels and seem to have deleterious effects on estimated GFR (eGFR) in comparison to ACE inhibitors in ADPKD76. In an animal model of ADPKD, calcium channel blockers promoted cyst growth77, but the findings of human studies are inconsistent73,78,79.

Proteinuria

As mentioned above, the incidence of proteinuria is increased in children with ADPKD. In the systematic review by Marlais et al., the prevalence of proteinuria in these children was 20% (96% CI 9–40%)19; however, this finding may also be influenced by tertiary centre bias. Proteinuria does not seem to be associated with hypertension but is one of the most established risk factors for progression of CKD in adults and children regardless of the cause of CKD80–85. Owing to its therapeutic and prognostic relevance, monitoring of proteinuria and/or albuminuria should be considered standard care for children with ADPKD (Box 5).

Proteinuria can be considered not only as a marker of CKD but also as a cause of further tubulointerstitial damage and fibrosis, as well as glomerular hypertrophy86. Reduction of proteinuria using ACE inhibitors or ARBs is associated with significant improvement in renal survival in patients with CKD87, although RCTs in children are lacking. Control of proteinuria is therefore an important aspect of current treatment recommendations for CKD67. In children with ADPKD who have proteinuria, ACE inhibitors or ARBs should be used as the primary treatment as in other chronic kidney diseases.

Albuminuria tends to be mild in adults with ADPKD; for example, in the TEMPO 3:4 study, the median albumin/creatinine ratio (ACR) was 3.2 mg/mmol. Of all patients, 49% of patients had moderate albuminuria (ACR ≥3 mg/mmol) and just 3.4% had severe albuminuria (ACR ≥30 mg/mmol)88. We therefore recommend measuring ACR in a laboratory rather than performing dipstick testing, which is a less sensitive and specific method.

Routine monitoring of cyst growth

In asymptomatic children, routine monitoring of cyst growth should not be performed too frequently as ultrasonography findings are very unlikely to influence clinical management decisions and the psychological burden of regular ‘cyst counting’ should be considered. Cyst number and TKV correlate with hypertension25,43–45, but ultrasonography cannot replace direct measurement of blood pressure, which remains essential in clinical practice. Although children with very-early-onset ADPKD have poorer outcomes89, no studies have examined whether the prediction of ‘rapid progressors’ by repeated imaging in children is feasible and clinically helpful. Our recommendation (Box 6) would change in the future if paediatric studies show a predictive value of kidney imaging on later progression to end-stage renal disease (ESRD; as has been shown in adults90) and a treatment to slow disease progression is licensed specifically for children who are at risk of early progression to ESRD.

As discussed below, ultrasonography examination is an essential tool in the investigation of symptomatic children, for example, when investigating urinary tract infections (UTIs), cyst haemorrhage, gross haematuria, renal stones or cyst infections. Before transition from paediatric to adult care, ultrasonography findings may also provide some guidance as to whether to refer the patient to a general practitioner or directly to a nephrologist.

Monitoring progression in ADPKD trials

Patient and renal survival are the most meaningful long-term outcomes in ADPKD trials but are difficult to assess in paediatric populations. GFR is nearly always within the normal range during childhood ADPKD19,33, thus eGFR decline is a suitable marker of disease progression only in the small subgroup of children with very advanced ADPKD89. Height-adjusted TKV (htTKV) on MRI is the most established imaging surrogate parameter for monitoring disease progression in adult ADPKD trials91. To date, only one study has investigated the correlation of MRI measurements with disease severity in children with ADPKD. This study found a correlation of MRI cyst volume and TKV with current hypertension status, as well as a predictive value of cyst volume for the development of hypertension43. In contrast to adults, kidneys in children with early ADPKD can usually be imaged within one ultrasonography viewing field (maximum dimension ~17 cm), which enables adequate measurements for volume calculation using the ellipsoid formula92. However, quantification of cyst number in older children is probably more accurate with MRI once multiple small cysts become too numerous for counting on ultrasonography. For TKV, MRI measurements seem to be slightly larger than ultrasonography measurements in children with ADPKD, with discrepancies mainly for larger kidneys43,48. Correlation of hypertension to kidney volume on renal ultrasonography has been demonstrated in three paediatric studies25,44,45. 3D ultrasonography is a promising new tool for TKV measurements in children but requires further validation48. As non-cooperative children require sedation for MRI, use of this approach does not seem to be warranted in a research setting without direct benefit for the child (Box 7). Use of MRI planimetry to measure TKV may be appropriate for adolescents in clinical trials or children with very large kidneys.

Lifestyle interventions and treatments

Maintenance of normal weight

No RCTs of lifestyle interventions with relevant outcome measures have been conducted in patients with ADPKD. However, there is no evidence to suggest that lifestyle recommendations for the general paediatric population, as well as those for children and adults with CKD, do not apply to children with ADPKD (Box 8). The importance of maintaining normal weight is underlined by the observation that obesity is an independent predictor of faster loss of renal function in adults with early ADPKD93.

Salt intake

The dietary salt intake of the general population of infants, toddlers and older children on a Western diet far exceeds the recommended amounts94. In adults with CKD, high salt intake is associated with higher blood pressure, proteinuria and progression to ESRD95–98. Higher sodium intake also blunts the antihypertensive and antiproteinuric effects of RAAS blockade99,100. In patients with ADPKD, urinary sodium excretion correlates with kidney growth98,101. Moreover, in patients with later-stage ADPKD, higher urinary sodium levels (a surrogate for sodium intake) increased the risk of a composite end point of a 50% reduction in eGFR, ESRD or death98. Few interventional trials exist, but restricting salt intake lowers blood pressure and proteinuria in adults with ADPKD or CKD102,103. In accordance with numerous guidelines for CKD, we recommend that children with ADPKD should aim to achieve the recommended intake for healthy children, which may require extra assistance (for example, advice from a dietician).

Water and protein intake

High water intake to suppress endogenous vasopressin production is often recommended for patients with ADPKD26,27. However, evidence from interventional and observational studies does not confirm a benefit of this intervention104, and a randomized trial is still ongoing105. Studies suggest that adults with ADPKD are more sensitive to water deprivation than those with IgA nephropathy and produce higher levels of endogenous vasopressin to reach similar levels of urine osmolality to those of healthy individuals106,107. Dehydration should therefore be avoided, and patients should be encouraged to drink to satisfy thirst108. A low-osmolar diet (low sodium, low protein and adjusted water intake to decrease urinary osmolality to <280 mOsM/kg (280 mmol/kg)) decreased the levels of endogenous copeptin (a surrogate marker of vasopressin) in a short study of adults with ADPKD, but a potential long-term benefit on cyst growth remains speculative109. In children with non-ADPKD CKD, an RCT did not find a beneficial effect of a low-protein diet on GFR decline110. Unnecessary protein restriction should be avoided in children to reduce the risk of malnutrition.

Vasopressin analogues

Vasopressin analogues are one of several treatment options for nocturnal enuresis in school-age children111. A 1994 study reported a significant increase in urinary frequency and a decrease in urinary concentrating ability in children with severe ADPKD (more than ten cysts)33. By contrast, children with ten or fewer cysts had a nonsignificantly increased self-reported urinary frequency and no decrease in concentrating ability compared with children of parents with ADPKD who did not have any cysts on ultrasonography. A study that included 16 children who were diagnosed with ADPKD because of their symptoms found that only 1 of these children presented with enuresis16; this frequency is probably similar to that of the general paediatric population. As vasopressin antagonists reduce the rate of cyst growth and eGFR loss in patients with ADPKD112,113, vasopressin analogues can reasonably be considered to be detrimental in these patients; therefore, it seems wise to prefer other treatment options for the management of nocturnal enuresis in children with ADPKD111.

Statins

In a prospective, double-blind RCT in 110 children and young adults aged 8–22 years with ADPKD and good renal function, the addition of pravastatin to lisinopril (with target blood pressure in the fiftieth to seventy-fifth percentile) resulted in a significantly slower increase in htTKV than placebo114. As expected, eGFR did not differ between the groups. Although LDL and total cholesterol levels did not correlate directly with clinical outcome variables (htTKV, albuminuria and LVMI), the statin-induced change in urinary biomarkers of endothelial dysfunction was associated with prospective change in htTKV115. Routine statin treatment for cardiovascular indications is more prevalent in adults than in children. A secondary analysis of the HALT-PKD trials reported no effect of self-reported statin use versus no statin use on TKV or composite end points in adults with ADPKD116. Therefore, the encouraging findings in the only controlled paediatric study of statin therapy in ADPKD published to date need to be balanced against the lack of evidence of beneficial effects on renal outcome in the uncontrolled adult study116 and the lack of regulatory approval of statins for ADPKD. A controlled trial in adults is ongoing117. Paediatric safety data for statins in large cohorts have been published only for children with familial hypercholesteremia118–121, and the risk of statin therapy in pregnancy is unclear122. We were therefore unable to reach a consensus on the use of statins to slow disease progression in children with ADPKD.

Vasopressin antagonists

Tolvaptan has been licensed to delay disease progression in adults with ADPKD who are likely to go on to develop ESRD112,113 and has also been shown to reduce ADPKD-related pain123. Currently, no direct data exist to support the use of vasopressin antagonists in children and adolescents with ADPKD, and no safety studies in this group have been published. However, a multinational, double-blind, placebo-controlled trial of tolvaptan in teenagers with ADPKD is currently underway124. Although early initiation of treatment resulting in a longer lifetime treatment period may theoretically lead to a greater absolute prevention of eGFR loss than that achieved with later treatment initiation125, the medium-term protection against relative eGFR loss is much lower in patients with preserved renal function than in those with more advanced CKD. Tolvaptan is known to cause occasional hepatic injury in adult ADPKD126, but the impact of this agent on liver enzymes in children is not yet known. In addition, treatment with vasopressin antagonists causes substantial polyuria, which is likely to affect sleep and daily activities and thus may influence quality of life. Patients are likely to require additional counselling and support to successfully adhere to such a disruptive treatment during adolescence.

mTOR inhibitors

Prospective RCTs did not find an eGFR benefit of mTOR inhibitors in adults with ADPKD, and these agents were associated with important adverse effects such as worsening proteinuria, hyperlipidaemia and cytopenias127–129. We therefore recommend that mTOR inhibitors should not be used in children and adolescents with classical ADPKD.

In patients with PKD1/TSC2 CGS, mTOR inhibitors are potentially beneficial as renal cysts have been reported to decrease in children with tuberous sclerosis receiving treatment with mTOR inhibitors for other indications130. However, as cyst volume does not automatically equate to GFR benefit127 and there is no published experience of these drugs in PKD1/TSC2 CGS, they should be reserved for the licensed indications of subependymal giant cell astrocytoma and large angiomyolipomas.

Somatostatin analogues

Use of somatostatin analogues to delay disease progression in ADPKD has been studied only in adults. RCTs indicate that these agents are beneficial in patients with severe liver disease but do not have a sustained beneficial effect on renal function131–135. No severe cases of ADPKD-related liver disease in children have been reported in the literature, and paediatric experience with these drugs is limited. We therefore recommend that somatostatin analogues should not be used in children with ADPKD.

Management of complications

Abdominal pain

Abdominal pain is reported in 10–20% of children with ADPKD16,33,136. As abdominal and back pain are very common symptoms among children and adolescents in general, further investigations and treatment need to be guided by acuity, intensity and associated findings137 (Box 9). Even in the early stages of ADPKD, episodes of nonspecific abdominal pain are frequently reported by adults and tend to be underestimated by physicians138. However, patients might have a biased perception of pain, especially if investigations for abdominal pain led to their incidental diagnosis of ADPKD. Chronic pain requires a multidisciplinary approach to avoid overtreatment or undertreatment and to improve self-management139. Chronic and/or high-dose use of nonsteroidal anti-inflammatory agents (NSAIDs) should be avoided because of potential renal adverse effects140,141.

Urinary tract and cyst infections

Cohort studies suggest an increased incidence of UTIs in children with ADPKD (up to 15–25%)6,16,33,37,136. These studies may be biased as imaging for UTI may have prompted the diagnosis of ADPKD. As no studies have suggested an increased incidence of complicated or prolonged infections in children with ADPKD, local standards for the diagnosis and treatment of UTI in otherwise healthy children should be applied.

Suspicion of upper UTI in children with ADPKD should lead to examination of urine (and blood) cultures, as well as renal ultrasonography, much the same as in otherwise healthy children142. Cyst infection is a very rare complication of childhood ADPKD. If suspected clinically or on ultrasonography imaging, experience in adults suggests that 18F-FDG–PET/computed tomography (CT) is superior to contrast CT or MRI to confirm the diagnosis and localize the infected cyst, but this approach can produce false-negative results143,144. Treatment of cyst infection has a high failure rate and requires long-term use of antibiotics145. Precise localization of an infected cyst can be extremely difficult in patients with many cysts but is necessary only for refractory infection when cyst drainage may be required.

Haematuria and cyst haemorrhage

Macroscopic haematuria is reported in 5–15% of children with ADPKD6,16,33,37,45,136,146. However, studies may overestimate the incidence, as imaging for haematuria may have prompted the diagnosis. Macroscopic haematuria is associated with enlarged TKV in adults147 but was not more common in children with severe versus moderate versus no cysts33, nor in children with very-early-onset disease versus those with later onset146. Gross haematuria before the age of 30–35 years is associated with worse renal survival in adults with ADPKD148,149. Observations in adults with severe cyst haemorrhage seem to suggest a benefit of treatment with tranexamic acid150,151, but the efficacy of this therapy has not been investigated in children.

Nephrolithiasis

Nephrolithiasis is an exceedingly rare complication in children with ADPKD, and ultrasonography should be used as the first-line imaging modality to rule out stones or other urinary tract obstructions. If kidney stones are found, additional risk factors for stone disease should be investigated, and a high fluid intake and symptomatic treatment are recommended.

Liver cysts

As the size and number of ADPKD-related liver cysts are known to increase in pregnancy, avoidance of exogenous oestrogens and hormone replacement therapy is generally recommended for women with ADPKD152. However, the prevalence of hepatic cysts in children with ADPKD is <5%, with no reports of severe cases6,16,33,136,146,153. The risk of future aggravated liver disease in young women with ADPKD considering hormonal contraceptive therapy should be balanced against the risk of unplanned pregnancy. Assessment of the burden of liver cysts and family history might assist in clinical decision-making.

Screening for extrarenal complications

Mitral valve prolapse

A systematic study published in 1995 reported mitral valve prolapse in 12% of children with ADPKD154. This prevalence was significantly higher than that of their healthy siblings (3%) but is within the range reported for healthy children and is lower than that reported for adults with ADPKD (25%)155–157. As children without a murmur are unlikely to have haemodynamically relevant mitral valve prolapse, they do not require echocardiographic screening for mitral valve prolapse (Box 10).

Intracranial aneurysm

In adults with ADPKD, screening for intracranial aneurysms is generally recommended only if additional risk factors are present such as a positive family history, previous intracranial aneurysms or a high-risk profession26,27,158,159. However, some authors disagree with this recommendation, arguing that screening is cost-effective160. Treatment strategies for unruptured intracranial aneurysms are still controversial. As rupture of intracranial aneurysm is an exceedingly rare complication in childhood161, routine screening is not justified. In rare cases with a positive family history and a strong desire to ease anxiety by screening, an individualized approach is justified.

Liver cysts

No reports exist of clinically relevant complications of ADPKD-related liver cysts in children6,16,33,37,146,153. Congenital hepatic fibrosis is not a feature of classical ADPKD. Ultrasonography of the liver may be a reasonable investigation at first presentation of children with suspected ADPKD if alternative diagnoses are being considered or in the case of acute abdominal pain. However, we do not recommend regular screening for liver cysts in children with confirmed ADPKD.

Referral to specialized centres

Newborn babies and infants with severe cystic disease comprise a heterogeneous group who pose numerous challenges to diagnosis and management. Extended genetic testing of these patients is recommended to inform genetic and prognostic counselling in a specialized centre. However, neonates or fetuses with hyperechogenic kidneys and a family history of ADPKD who do not have symptoms or enlarged kidneys should not be considered to have severe disease. Children with TSC2/PKD1 CGS typically have severe polycystic kidney disease and may reach ESRD in young adulthood162,163. We recommend referral to a specialized centre and multidisciplinary care for these patients.

Psychosocial aspects

The consensus group shares the view of a current multidisciplinary position statement on ADPKD that emphasizes the need for “a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family”164. Although young adults with ADPKD usually carry a much lower burden of physical impairment than older patients, they have to make lifestyle, career and family planning choices that will have lifelong effects. Studies in families with ADPKD have shown a high psychological burden of both ‘genetic guilt’ and anxiety about future health problems.

We recommend that families of children with ADPKD should be encouraged to discuss the risk of disease transmission with their children (Box 11). Parents affected by inheritable disease often find communication with their children difficult and desire professional assistance, including developmentally appropriate disease information and advice on managing their children’s emotional reactions21. Qualitative studies show that avoiding such discussions can be a source of family tensions through misunderstanding, blame and secrecy23, whereas open communication with younger children promotes effective coping strategies and makes families more resilient23. Multi-family discussion groups can be a valuable tool for promoting such intrafamilial discussions165.

Several lifestyle interventions can be recommended for patients with ADPKD (see above), irrespective of their CKD stage. As teenage and young-adult years provide the unique opportunity to establish healthy living habits without having to break previous habits, this period is an important age for counselling. Relevant messages include the importance of a healthy, low-salt diet, adequate fluid intake, regular physical exercise, avoiding obesity, abstention from smoking and avoidance of nephrotoxic medication. Young women should also be counselled to avoid high-oestrogen-containing contraception products because of potential exacerbation of later liver disease.

Issues of genetic guilt or fear of the future disease course can have a substantial impact on the psychological well-being of young people and families affected by ADPKD. Integrated care should therefore include active inquiry about anxieties and sources of psychological support. Positive messages that can be used to promote a proactive attitude towards disease management are, for example, ‘you are not ill’, ‘you have the opportunity and time to influence later outcome by preventive measures’ or ‘many career choices are open to you’. Young adults may also value discussion about wise disclosure of their renal disease to outsiders. Contact with affected peers via patient communities should be encouraged. Finally, reminding parents of their value as positive role models may be helpful.

Discontinuity of care because of transfer from paediatric to adult nephrology care is an important risk factor for adverse outcome in more severely affected individuals. Local and international guidance on transition should be followed to prevent loss of medical follow-up166.

Conclusions

Although the main burden of disease in ADPKD does not occur until adulthood, a substantial proportion of paediatric and adolescent patients have treatable disease manifestations and a small percentage have symptomatic disease or very-early-onset disease in infancy. This consensus group hopes that our recommendations will improve the care of children with or at risk of ADPKD. We recommend the provision of balanced counselling for families with respect to diagnostic screening, regular monitoring of blood pressure and proteinuria and the avoidance of frequent imaging to monitor cyst growth. We also provide guidance on managing complications, lifestyle interventions and psychosocial aspects. As the pharmacological management of adult ADPKD advances and the results of a paediatric trial of tolvaptan are pending, future challenges will include defining in medical, psychological and economic terms which patients will benefit from early initiation of treatment to delay disease progression.

Supplementary information

References

  1. Dalgaard OZ Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families Acta Med. Scand. Suppl. 1957 328 1 255 13469269 PubMed
  2. Willey CJ Prevalence of autosomal dominant polycystic kidney disease in the European Union Nephrol. Dial. Transplant. 2017 32 1356 1363 27325254 10.1093/ndt/gfw240 PMC5837385 PubMed DOI
  3. Lanktree MB Prevalence estimates of polycystic kidney and liver disease by population sequencing J. Am. Soc. Nephrol. 2018 29 2593 2600 30135240 10.1681/ASN.2018050493 PMC6171271 PubMed DOI
  4. Solazzo A The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition PLOS ONE 2018 13 e0190430 29338003 10.1371/journal.pone.0190430 PMC5770025 PubMed DOI
  5. Audrézet M-P Comprehensive PKD1 and PKD2 mutation analysis in prenatal autosomal dominant polycystic kidney disease J. Am. Soc. Nephrol. 2016 27 722 729 26139440 10.1681/ASN.2014101051 PMC4769188 PubMed DOI
  6. Boyer O Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth Pediatr. Nephrol. 2007 22 380 388 17124604 10.1007/s00467-006-0327-8 PubMed DOI
  7. Zerres K Rudnik-Schöneborn S Deget F Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft für Pädiatrische Nephrologie J. Med. Genet. 1993 30 583 588 8411032 10.1136/jmg.30.7.583 PMC1016459 PubMed DOI
  8. Srivastava T Simon SD Alon US High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood Pediatr. Nephrol. 1999 13 13 18 10100283 10.1007/s004670050555 PubMed DOI
  9. Espié E Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996–2006 Pediatr. Infect. Dis. J. 2008 27 595 601 18520972 10.1097/INF.0b013e31816a062f PubMed DOI
  10. Ong AC Devuyst O Knebelmann B Walz G ERA-EDTA Working Group for Inherited Kidney Diseases Autosomal dominant polycystic kidney disease: the changing face of clinical management Lancet 2015 385 1993 2002 26090645 10.1016/S0140-6736(15)60907-2 PubMed DOI
  11. König JC Titieni A Konrad M & NEOCYST Consortium. Network for early onset cystic kidney diseases-a comprehensive multidisciplinary approach to hereditary cystic kidney diseases in childhood Front. Pediatr. 2018 6 24 29497606 10.3389/fped.2018.00024 PMC5819567 PubMed DOI
  12. American Academy of Pediatrics Steering Committee on Quality Improvement and Management Classifying recommendations for clinical practice guidelines Pediatrics 2004 114 874 877 15342869 10.1542/peds.2004-1260 PubMed DOI
  13. Flynn JT Clinical practice guideline for screening and management of high blood pressure in children and adolescents Pediatrics 2017 140 e20171904 28827377 10.1542/peds.2017-1904 PubMed DOI
  14. Rechter SD Clinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease PLOS ONE 2017 12 e0185779 28961265 10.1371/journal.pone.0185779 PMC5621697 PubMed DOI
  15. Tong A A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research Nephrol. Dial. Transplant. 2015 30 790 800 25637642 10.1093/ndt/gfv010 PubMed DOI
  16. Mekahli D Woolf AS Bockenhauer D Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms Pediatr. Nephrol. 2010 25 2275 2282 20683618 10.1007/s00467-010-1617-8 PubMed DOI
  17. Borry P Stultiens L Nys H Cassiman J-J Dierickx K Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers Clin. Genet. 2006 70 374 381 17026616 10.1111/j.1399-0004.2006.00692.x PubMed DOI
  18. Botkin JR Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents Am. J. Hum. Genet. 2015 97 6 21 26140447 10.1016/j.ajhg.2015.05.022 PMC4570999 PubMed DOI
  19. Marlais M Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis Arch. Dis. Child. 2016 101 1142 1147 27288429 10.1136/archdischild-2015-310221 PubMed DOI
  20. Kramers BJ Storm M Gansevoort RT Familiaire cystenieren: jongvolwassen familieleden screenen of niet? [Dutch] Ned. Tijdschr. Geneeskd 2017 161 D1942 29145907 PubMed
  21. Metcalfe A Plumridge G Coad J Shanks A Gill P Parents’ and children’s communication about genetic risk: a qualitative study, learning from families’ experiences Eur. J. Hum. Genet. 2011 19 640 646 21326287 10.1038/ejhg.2010.258 PMC3097166 PubMed DOI
  22. Metcalfe A Coad J Plumridge GM Gill P Farndon P Family communication between children and their parents about inherited genetic conditions: a meta-synthesis of the research Eur. J. Hum. Genet. 2008 16 1193 1200 18431405 10.1038/ejhg.2008.84 PubMed DOI
  23. Rowland E Metcalfe A Communicating inherited genetic risk between parent and child: a meta-thematic synthesis Int. J. Nurs. Stud. 2013 50 870 880 23026156 10.1016/j.ijnurstu.2012.09.002 PubMed DOI
  24. Pei Y Unified criteria for ultrasonographic diagnosis of ADPKD J. Am. Soc. Nephrol. 2009 20 205 212 18945943 10.1681/ASN.2008050507 PMC2615723 PubMed DOI
  25. Seeman T Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease Blood Press. Monit. 2003 8 107 110 12900587 10.1097/01.mbp.0000085762.28312.4a PubMed DOI
  26. Ars E Spanish guidelines for the management of autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant. 2014 29 iv95 iv105 25165191 10.1093/ndt/gfu186 PubMed DOI
  27. Chapman AB Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int. 2015 88 17 27 25786098 10.1038/ki.2015.59 PMC4913350 PubMed DOI
  28. Rangan GK KHA-CARI autosomal dominant polycystic kidney disease guideline: screening for polycystic kidney disease Semin. Nephrol. 2015 35 557 564 26718159 10.1016/j.semnephrol.2015.10.004 PubMed DOI
  29. Gimpel C Perinatal diagnosis, management, and follow-up of cystic renal diseases: a clinical practice recommendation with systematic literature reviews JAMA Pediatr. 2018 172 74 86 29181500 10.1001/jamapediatrics.2017.3938 PubMed DOI
  30. Gimpel C Imaging of kidney cysts and cystic kidney diseases in children: an International Working Group Consensus Statement Radiology 2019 290 769 782 30599104 10.1148/radiol.2018181243 PMC6394734 PubMed DOI
  31. Gabow PA Kimberling WJ Strain JD Manco-Johnson ML Johnson AM Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children J. Am. Soc. Nephrol. 1997 8 105 110 9013454 10.1681/ASN.V81105 PubMed DOI
  32. Sedman A Autosomal dominant polycystic kidney disease in childhood: a longitudinal study Kidney Int. 1987 31 1000 1005 3295357 10.1038/ki.1987.98 PubMed DOI
  33. Fick GM The spectrum of autosomal dominant polycystic kidney disease in children J. Am. Soc. Nephrol. 1994 4 1654 1660 8011974 10.1681/ASN.V491654 PubMed DOI
  34. Reed B Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease Am. J. Kidney Dis. 2010 56 50 56 20452711 10.1053/j.ajkd.2010.02.349 PubMed DOI
  35. Ravine D Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 Lancet 1994 343 824 827 7908078 10.1016/s0140-6736(94)92026-5 PubMed DOI
  36. Pei Y Imaging-based diagnosis of autosomal dominant polycystic kidney disease J. Am. Soc. Nephrol. 2015 26 746 753 25074509 10.1681/ASN.2014030297 PMC4341484 PubMed DOI
  37. Fencl F Genotype–phenotype correlation in children with autosomal dominant polycystic kidney disease Pediatr. Nephrol. 2009 24 983 989 19194729 10.1007/s00467-008-1090-9 PubMed DOI
  38. Parfrey PS The diagnosis and prognosis of autosomal dominant polycystic kidney disease N. Engl. J. Med. 1990 323 1085 1090 2215575 10.1056/NEJM199010183231601 PubMed DOI
  39. Bear JC Parfrey PS Morgan JM Martin CJ Cramer BC Autosomal dominant polycystic kidney disease: new information for genetic counselling Am. J. Med. Genet. 1992 43 548 553 1605247 10.1002/ajmg.1320430309 PubMed DOI
  40. Elles RG Diagnosis of adult polycystic kidney disease by genetic markers and ultrasonographic imaging in a voluntary family register J. Med. Genet. 1994 31 115 120 8182715 10.1136/jmg.31.2.115 PMC1049671 PubMed DOI
  41. Nicolau C Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US sensitivity for diagnosis Radiology 1999 213 273 276 10540671 10.1148/radiology.213.1.r99oc05273 PubMed DOI
  42. Papadopoulou D Tsakiris D Papadimitriou M The use of ultrasonography and linkage studies for early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) Ren. Fail. 1999 21 67 84 10048119 10.3109/08860229909066971 PubMed DOI
  43. Cadnapaphornchai MA Masoumi A Strain JD McFann K Schrier RW Magnetic resonance imaging of kidney and cyst volume in children with ADPKD Clin. J. Am. Soc. Nephrol. 2011 6 369 376 21115621 10.2215/CJN.03780410 PMC3052228 PubMed DOI
  44. Cadnapaphornchai MA McFann K Strain JD Masoumi A Schrier RW Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension Kidney Int. 2008 74 1192 1196 18716604 10.1038/ki.2008.397 PMC2574635 PubMed DOI
  45. Fick-Brosnahan GM Tran ZV Johnson AM Strain JD Gabow PA Progression of autosomal-dominant polycystic kidney disease in children Kidney Int. 2001 59 1654 1662 11318935 10.1046/j.1523-1755.2001.0590051654.x PubMed DOI
  46. McHugh K Stringer DA Hebert D Babiak CA Simple renal cysts in children: diagnosis and follow-up with US Radiology 1991 178 383 385 1987597 10.1148/radiology.178.2.1987597 PubMed DOI
  47. Iliuta I-A Polycystic kidney disease without an apparent family history J. Am. Soc. Nephrol. 2017 28 2768 2776 28522688 10.1681/ASN.2016090938 PMC5576926 PubMed DOI
  48. Breysem L 3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease Pediatr. Nephrol. 2018 33 827 835 29306987 10.1007/s00467-017-3862-6 PubMed DOI
  49. Lanktree MB Iliuta I-A Haghighi A Song X Pei Y Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant. 2018 10.1093/ndt/gfy261 30165646 DOI PubMed
  50. Rossetti S Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease Kidney Int. 2009 75 848 855 19165178 10.1038/ki.2008.686 PMC2813773 PubMed DOI
  51. Bergmann C Mutations in multiple PKD genes may explain early and severe polycystic kidney disease J. Am. Soc. Nephrol. 2011 22 2047 2056 22034641 10.1681/ASN.2010101080 PMC3279997 PubMed DOI
  52. Bergmann C Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses Front. Pediatr. 2018 5 221 29479522 10.3389/fped.2017.00221 PMC5811498 PubMed DOI
  53. Brook-Carter PT Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease — a contiguous gene syndrome Nat. Genet. 1994 8 328 332 7894481 10.1038/ng1294-328 PubMed DOI
  54. Bergmann C ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies Pediatr. Nephrol. 2015 30 15 30 24584572 10.1007/s00467-013-2706-2 PMC4240914 PubMed DOI
  55. Chapman AB Stepniakowski K Rahbari-Oskoui F Hypertension in autosomal dominant polycystic kidney disease Adv. Chronic Kidney Dis. 2010 17 153 163 20219618 10.1053/j.ackd.2010.01.001 PMC2845913 PubMed DOI
  56. Kelleher CL McFann KK Johnson AM Schrier RW Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U. S. population Am. J. Hypertens. 2004 17 1029 1034 15533729 10.1016/j.amjhyper.2004.06.020 PubMed DOI
  57. Massella L Prevalence of hypertension in children with early-stage ADPKD Clin. J. Am. Soc. Nephrol. 2018 13 874 883 29674338 10.2215/CJN.11401017 PMC5989684 PubMed DOI
  58. Stergiou GS Reproducibility of home and ambulatory blood pressure in children and adolescents Blood Press. Monit. 2005 10 143 147 15923815 10.1097/00126097-200506000-00005 PubMed DOI
  59. Brady TM Fivush B Flynn JT Parekh R Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension J. Pediatr. 2008 152 73 78 18154904 10.1016/j.jpeds.2007.05.053 PubMed DOI
  60. Agarwal R Andersen MJ Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease Kidney Int. 2006 69 406 411 16408134 10.1038/sj.ki.5000081 PubMed DOI
  61. Wühl E Hadtstein C Mehls O Schaefer F Escape Trial Group Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure Pediatr. Res. 2004 55 492 497 14630977 10.1203/01.PDR.0000106863.90996.76 PubMed DOI
  62. Samuels J Ambulatory blood pressure patterns in children with chronic kidney disease Hypertension 2012 60 43 50 22585950 10.1161/HYPERTENSIONAHA.111.189266 PMC3439139 PubMed DOI
  63. Ogedegbe G Schoenthaler A A systematic review of the effects of home blood pressure monitoring on medication adherence J. Clin. Hypertens. (Greenwich) 2006 8 174 180 16522994 10.1111/j.1524-6175.2006.04872.x PMC8109348 PubMed DOI
  64. Stergiou GS Yiannes NG Rarra VC Panagiotakos DB Home blood pressure normalcy in children and adolescents: the Arsakeion School study J. Hypertens. 2007 25 1375 1379 17563558 10.1097/HJH.0b013e328122d3fc PubMed DOI
  65. Oh J Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure Circulation 2002 106 100 105 12093777 10.1161/01.cir.0000020222.63035.c0 PubMed DOI
  66. ESCAPE Trial Group Strict blood-pressure control and progression of renal failure in children N. Engl. J. Med. 2009 361 1639 1650 19846849 10.1056/NEJMoa0902066 PubMed DOI
  67. International Society of Nephrology Chapter 3: management of progression and complications of CKD Kidney Int. Suppl. 2013 3 73 90 10.1038/kisup.2012.66 PMC4283680 25598999 DOI PubMed
  68. Schrier RW Blood pressure in early autosomal dominant polycystic kidney disease N. Engl. J. Med. 2014 371 2255 2266 25399733 10.1056/NEJMoa1402685 PMC4343258 PubMed DOI
  69. Cadnapaphornchai MA McFann K Strain JD Masoumi A Schrier RW Prospective change in renal volume and function in children with ADPKD Clin. J. Am. Soc. Nephrol. 2009 4 820 829 19346430 10.2215/CJN.02810608 PMC2666428 PubMed DOI
  70. Wright JT Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 2002 288 2421 2431 12435255 10.1001/jama.288.19.2421 PubMed DOI
  71. Zeltner R Poliak R Stiasny B Schmieder RE Schulze BD Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant. 2008 23 573 579 17984104 10.1093/ndt/gfm731 PubMed DOI
  72. van Dijk MA Breuning MH Duiser R van Es LA Westendorp RGJ No effect of enalapril on progression in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant. 2003 18 2314 2320 14551359 10.1093/ndt/gfg417 PubMed DOI
  73. Ecder T Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease Am. J. Kidney Dis. 2000 35 427 432 10692268 10.1016/s0272-6386(00)70195-8 PubMed DOI
  74. Xue C Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials Oncotarget 2015 6 42515 42529 26636542 10.18632/oncotarget.6452 PMC4767449 PubMed DOI
  75. Torres VE Angiotensin blockade in late autosomal dominant polycystic kidney disease N. Engl. J. Med. 2014 371 2267 2276 25399731 10.1056/NEJMoa1402686 PMC4284824 PubMed DOI
  76. Ecder T Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease Am. J. Nephrol. 2001 21 98 103 11359016 10.1159/000046231 PubMed DOI
  77. Nagao S Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+rat Kidney Int. 2008 73 269 277 17943077 10.1038/sj.ki.5002629 PubMed DOI
  78. Nutahara K Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease Nephron. Clin. Pract. 2005 99 c18 c23 15637459 10.1159/000081790 PubMed DOI
  79. Kanno Y Suzuki H Okada H Takenaka T Saruta T Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease QJM 1996 89 65 70 8730344 10.1093/oxfordjournals.qjmed.a030139 PubMed DOI
  80. Ruggenenti P Perna A Mosconi L Pisoni R Remuzzi G Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. ‘Gruppo Italiano di Studi Epidemiologici in Nefrologia’ (GISEN) Kidney Int. 1998 53 1209 1216 9573535 10.1046/j.1523-1755.1998.00874.x PubMed DOI
  81. Peterson JC Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study Ann. Intern. Med. 1995 123 754 762 7574193 10.7326/0003-4819-123-10-199511150-00003 PubMed DOI
  82. Wühl E Mehls O Schaefer F ESCAPE Trial Group Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure Kidney Int. 2004 66 768 776 15253732 10.1111/j.1523-1755.2004.00802.x PubMed DOI
  83. Ardissino G Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project Pediatr. Nephrol. 2004 19 172 177 14673629 10.1007/s00467-003-1268-0 PubMed DOI
  84. González Celedón C Bitsori M Tullus K Progression of chronic renal failure in children with dysplastic kidneys Pediatr. Nephrol. 2007 22 1014 1020 17380351 10.1007/s00467-007-0459-5 PubMed DOI
  85. Ishikura K Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study Nephrol. Dial. Transplant. 2014 29 878 884 24516225 10.1093/ndt/gfu012 PubMed DOI
  86. Ding L-H TLR2-MyD88-NF-κB pathway is involved in tubulointerstitial inflammation caused by proteinuria Int. J. Biochem. Cell Biol. 2015 69 114 120 26485683 10.1016/j.biocel.2015.10.014 PubMed DOI
  87. Heerspink HJ Kröpelin TF Hoekman J de Zeeuw D Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis J. Am. Soc. Nephrol. 2015 26 2055 2064 25421558 10.1681/ASN.2014070688 PMC4520175 PubMed DOI
  88. Gansevoort RT Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 trial Nephrol. Dial Transplant 2016 31 1887 1894 26681730 10.1093/ndt/gfv422 PMC6367945 PubMed DOI
  89. Nowak KL Cadnapaphornchai MA Chonchol MB Schrier RW Gitomer B Long-term outcomes in patients with very-early onset autosomal dominant polycystic kidney disease Am. J. Nephrol. 2016 44 171 178 27548646 10.1159/000448695 PMC5098215 PubMed DOI
  90. Yu, A. S. L. et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 95 , 1253–1261 (2019). 10.1016/j.kint.2018.12.023 PMC6478515 30922668 DOI PubMed
  91. Jo WR Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: a systematic review and meta-analysis Eur. J. Radiol. 2017 95 56 65 28987699 10.1016/j.ejrad.2017.07.023 PubMed DOI
  92. Jones TB Riddick LR Harpen MD Dubuisson RL Samuels D Ultrasonographic determination of renal mass and renal volume J. Ultrasound Med. 1983 2 151 154 6854718 10.7863/jum.1983.2.4.151 PubMed DOI
  93. Nowak KL Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease J. Am. Soc. Nephrol. 2018 29 571 578 29118087 10.1681/ASN.2017070819 PMC5791072 PubMed DOI
  94. Butte NF Nutrient intakes of US infants, toddlers, and preschoolers meet or exceed dietary reference intakes J. Acad. Nutr. Diet. 2010 110 S27 S37 10.1016/j.jada.2010.09.004 21092766 DOI PubMed
  95. Nerbass FB Pecoits-Filho R McIntyre NJ McIntyre CW Taal MW High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients Eur. J. Clin. Nutr. 2015 69 786 790 25293433 10.1038/ejcn.2014.215 PubMed DOI
  96. Smyth A Diet and major renal outcomes: a prospective cohort study. The NIH-AARP diet and health study J. Ren. Nutr. 2016 26 288 298 26975776 10.1053/j.jrn.2016.01.016 PubMed DOI
  97. Vegter S Sodium intake, ACE inhibition, and progression to ESRD J. Am. Soc. Nephrol. 2012 23 165 173 22135311 10.1681/ASN.2011040430 PMC3269916 PubMed DOI
  98. Torres VE Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease Kidney Int. 2017 91 493 500 27993381 10.1016/j.kint.2016.10.018 PMC5237414 PubMed DOI
  99. Heerspink HJL The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J. Prev. Cardiol. 2014 21 299 309 10.1177/2047487313510678 24191305 DOI PubMed
  100. Vogt L Waanders F Boomsma F de Zeeuw D Navis G Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan J. Am. Soc. Nephrol. 2008 19 999 1007 18272844 10.1681/ASN.2007060693 PMC2386733 PubMed DOI
  101. Torres VE Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease Clin. J. Am. Soc. Nephrol. 2011 6 640 647 21088290 10.2215/CJN.03250410 PMC3082424 PubMed DOI
  102. Doulton TW The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients J. Hypertens. 2006 24 939 945 16612257 10.1097/01.hjh.0000222765.30348.0d PubMed DOI
  103. McMahon EJ Campbell KL Bauer JD Mudge DW Altered dietary salt intake for people with chronic kidney disease Cochrane Database Syst. Rev. 2015 2 CD010070 10.1002/14651858.CD010070.pub2 25691262 DOI PubMed
  104. Higashihara E Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol. Dial. Transplant. 2014 29 1710 1719 24739484 10.1093/ndt/gfu093 PMC4145867 PubMed DOI
  105. Wong ATY Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD) BMJ Open 2018 8 e018794 29358433 10.1136/bmjopen-2017-018794 PMC5780847 PubMed DOI
  106. Zittema D Urine concentrating capacity, vasopressin and copeptin in ADPKD and IgA nephropathy patients with renal impairment PLOS ONE 2017 12 e0169263 28081165 10.1371/journal.pone.0169263 PMC5231267 PubMed DOI
  107. Zittema D Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment Clin. J. Am. Soc. Nephrol. 2012 7 906 913 22516290 10.2215/CJN.11311111 PubMed DOI
  108. Campbell KL Rangan GK Lopez-Vargas P Tong A KHA-CARI autosomal dominant polycystic kidney disease guideline: diet and lifestyle management Semin. Nephrol. 2015 35 572 581.e17 26718161 10.1016/j.semnephrol.2015.10.008 PubMed DOI
  109. Amro OW Paulus JK Noubary F Perrone RD Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial Am. J. Kidney Dis. 2016 68 882 891 27663039 10.1053/j.ajkd.2016.07.023 PMC5123924 PubMed DOI
  110. Wingen AM Fabian-Bach C Schaefer F Mehls O Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children Lancet 1997 349 1117 1123 9113009 10.1016/s0140-6736(96)09260-4 PubMed DOI
  111. Neveus, T. et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children’s Continence Society. J. Urol. 183 , 441–447 (2010). 10.1016/j.juro.2009.10.043 20006865 DOI PubMed
  112. Torres VE Tolvaptan in patients with autosomal dominant polycystic kidney disease N. Engl. J. Med. 2012 367 2407 2418 23121377 10.1056/NEJMoa1205511 PMC3760207 PubMed DOI
  113. Torres VE Tolvaptan in later-stage autosomal dominant polycystic kidney disease N. Engl. J. Med. 2017 377 1930 1942 29105594 10.1056/NEJMoa1710030 PubMed DOI
  114. Cadnapaphornchai MA Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease Clin. J. Am. Soc. Nephrol. 2014 9 889 896 24721893 10.2215/CJN.08350813 PMC4011448 PubMed DOI
  115. Klawitter J Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease Clin. J. Am. Soc. Nephrol. 2015 10 1534 1541 26224879 10.2215/CJN.11331114 PMC4559520 PubMed DOI
  116. Brosnahan G Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials Curr. Hypertens. Rev. 2017 13 109 120 28460625 10.2174/1573402113666170427142815 PMC5688015 PubMed DOI
  117. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03273413 (2018).
  118. Braamskamp MJAM Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study J. Clin. Lipidol. 2015 9 741 750 26687694 10.1016/j.jacl.2015.07.011 PubMed DOI
  119. Canas JA A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes Pediatr. Diabetes 2015 16 79 89 25418907 10.1111/pedi.12245 PubMed DOI
  120. Langslet G Breazna A Drogari EA 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia J. Clin. Lipidol. 2016 10 1153 1162 27678432 10.1016/j.jacl.2016.05.010 PubMed DOI
  121. Carreau V Girardet J-P Bruckert E Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability Paediatr. Drugs 2011 13 267 275 21692550 10.2165/11591650-000000000-00000 PubMed DOI
  122. Karalis DG Hill AN Clifton S Wild RA The risks of statin use in pregnancy: a systematic review J. Clin. Lipidol. 2016 10 1081 1090 27678424 10.1016/j.jacl.2016.07.002 PubMed DOI
  123. Casteleijn NF Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial Am. J. Kidney Dis. 2017 69 210 219 27856088 10.1053/j.ajkd.2016.08.028 PMC5497700 PubMed DOI
  124. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02964273 (2019).
  125. Grantham JJ Rationale for early treatment of polycystic kidney disease Pediatr. Nephrol. 2015 30 1053 1062 25022529 10.1007/s00467-014-2882-8 PubMed DOI
  126. Watkins PB Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of Clinical Trials Database Drug Saf. 2015 38 1103 1113 26188764 10.1007/s40264-015-0327-3 PMC4608984 PubMed DOI
  127. Walz G Everolimus in patients with autosomal dominant polycystic kidney disease N. Engl. J. Med. 2010 363 830 840 20581392 10.1056/NEJMoa1003491 PubMed DOI
  128. Serra AL Sirolimus and kidney growth in autosomal dominant polycystic kidney disease N. Engl. J. Med. 2010 363 820 829 20581391 10.1056/NEJMoa0907419 PubMed DOI
  129. Stallone G Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study Nephrol. Dial. Transplant. 2012 27 3560 3567 22785114 10.1093/ndt/gfs264 PubMed DOI
  130. Siroky BJ Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor J. Pediatr. 2017 187 318 322 28600153 10.1016/j.jpeds.2017.05.015 PubMed DOI
  131. Hogan MC Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J. Am. Soc. Nephrol. 2010 21 1052 1061 20431041 10.1681/ASN.2009121291 PMC2900957 PubMed DOI
  132. Caroli A Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial Lancet 2013 382 1485 1495 23972263 10.1016/S0140-6736(13)61407-5 PubMed DOI
  133. van Keimpema L Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 2009 137 1661 1668 19646443 10.1053/j.gastro.2009.07.052 PubMed DOI
  134. Ruggenenti P Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int. 2005 68 206 216 15954910 10.1111/j.1523-1755.2005.00395.x PubMed DOI
  135. Meijer E Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial JAMA 2018 320 2010 2019 30422235 10.1001/jama.2018.15870 PMC6248170 PubMed DOI
  136. Helal I Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease Clin. J. Am. Soc. Nephrol. 2011 6 2439 2443 21903987 10.2215/CJN.01010211 PMC3186452 PubMed DOI
  137. Swain MS An international survey of pain in adolescents BMC Public Health 2014 14 447 24885027 10.1186/1471-2458-14-447 PMC4046513 PubMed DOI
  138. Baker A Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians. Clin Kidney J. 2015 8 531 537 10.1093/ckj/sfv060 PMC4581379 26413277 DOI PubMed
  139. Di Lorenzo C Chronic abdominal pain in children: a clinical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition J. Pediatr. Gastroenterol. Nutr. 2005 40 245 248 15735475 10.1097/01.mpg.0000155367.44628.21 PubMed DOI
  140. Ungprasert P Cheungpasitporn W Crowson CS Matteson EL Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies Eur. J. Intern. Med. 2015 26 285 291 25862494 10.1016/j.ejim.2015.03.008 PubMed DOI
  141. Nderitu P Doos L Jones PW Davies SJ Kadam UT Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review Fam. Pract. 2013 30 247 255 23302818 10.1093/fampra/cms086 PubMed DOI
  142. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management Roberts KB Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months Pediatrics 2011 128 595 610 21873693 10.1542/peds.2011-1330 PubMed DOI
  143. Neuville M Hustinx R Jacques J Krzesinski J-M Jouret F Diagnostic algorithm in the management of acute febrile abdomen in patients with autosomal dominant polycystic kidney disease PLOS ONE 2016 11 e0161277 27529555 10.1371/journal.pone.0161277 PMC4987061 PubMed DOI
  144. Kim H Clinical experience with white blood cell-PET/CT in autosomal dominant polycystic kidney disease patients with suspected cyst infection: a prospective case series Nephrology (Carlton) 2018 23 661 668 28565035 10.1111/nep.13080 PubMed DOI
  145. Lantinga MA Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review Nephrol. Dial. Transplant. 2017 32 144 150 26908766 10.1093/ndt/gfv452 PubMed DOI
  146. Shamshirsaz A Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome Kidney Int. 2005 68 2218 2224 16221221 10.1111/j.1523-1755.2005.00678.x PubMed DOI
  147. Gabow PA Duley I Johnson AM Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease Am. J. Kidney Dis. 1992 20 140 143 1496966 10.1016/s0272-6386(12)80541-5 PubMed DOI
  148. Johnson AM Gabow PA Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease J. Am. Soc. Nephrol. 1997 8 1560 1567 9335384 10.1681/ASN.V8101560 PubMed DOI
  149. Cornec-Le Gall E The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease J. Am. Soc. Nephrol. 2016 27 942 951 26150605 10.1681/ASN.2015010016 PMC4769200 PubMed DOI
  150. Yao Q Treatment of persistent gross hematuria with tranexamic acid in autosomal dominant polycystic kidney disease Kidney Blood Press. Res. 2017 42 156 164 28395294 10.1159/000474961 PubMed DOI
  151. Peces R Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria Nefrologia 2012 32 160 165 22425801 10.3265/Nefrologia.pre2011.Dec.11210 PubMed DOI
  152. Savige J Mallett A Tunnicliffe DJ Rangan GK KHA-CARI autosomal dominant polycystic kidney disease guideline: management of polycystic liver disease Semin. Nephrol. 2015 35 618 622 26718168 10.1016/j.semnephrol.2015.10.015 PubMed DOI
  153. Tee JB Acott PD McLellan DH Crocker JFS Phenotypic heterogeneity in pediatric autosomal dominant polycystic kidney disease at first presentation: a single-center, 20-year review Am. J. Kidney Dis. 2004 43 296 303 14750095 10.1053/j.ajkd.2003.10.017 PubMed DOI
  154. Ivy DD Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease J. Am. Soc. Nephrol. 1995 5 2032 2036 7579051 10.1681/ASN.V5122032 PubMed DOI
  155. Warth DC Prevalence of mitral valve prolapse in normal children J. Am. Coll. Cardiol. 1985 5 1173 1177 3989128 10.1016/s0735-1097(85)80021-8 PubMed DOI
  156. Arfken CL Schulman P McLaren MJ Lachman AS Mitral valve prolapse and body habitus in children Pediatr. Cardiol. 1993 14 33 36 8456019 10.1007/BF00794842 PubMed DOI
  157. Hossack KF Leddy CL Johnson AM Schrier RW Gabow PA Echocardiographic findings in autosomal dominant polycystic kidney disease N. Engl. J. Med. 1988 319 907 912 3419455 10.1056/NEJM198810063191404 PubMed DOI
  158. Lee VW KHA-CARI autosomal dominant polycystic kidney disease guideline: management of intracranial aneurysms Semin. Nephrol. 2015 35 612 617 26718167 10.1016/j.semnephrol.2015.10.014 PubMed DOI
  159. Luciano RL Dahl NK Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management Nephrol. Dial. Transplant. 2014 29 247 254 24215018 10.1093/ndt/gft437 PubMed DOI
  160. Flahault A Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective Kidney Int. 2018 93 716 726 29061331 10.1016/j.kint.2017.08.016 PubMed DOI
  161. Kubo S A 4-year-old girl with autosomal dominant polycystic kidney disease complicated by a ruptured intracranial aneurysm Eur. J. Pediatr. 2004 163 675 677 15322866 10.1007/s00431-004-1528-4 PubMed DOI
  162. Sampson JR Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene Am. J. Hum. Genet. 1997 61 843 851 9382094 10.1086/514888 PMC1716004 PubMed DOI
  163. Castagnetti M Vezzù B Laverda A Zampieri S Rigamonti W Urological counseling and followup in pediatric tuberous sclerosis complex J. Urol. 2007 178 2155 2159 17870119 10.1016/j.juro.2007.07.058 PubMed DOI
  164. Harris T European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. European ADPKD Forum and Multispecialist Roundtable participants Nephrol. Dial. Transplant. 2018 33 563 573 29309655 10.1093/ndt/gfx327 PMC6018982 PubMed DOI
  165. Socio-Psychological Research in Genomics (SPRinG) Collaboration Developing an intervention to facilitate family communication about inherited genetic conditions, and training genetic counsellors in its delivery Eur. J. Hum. Genet. 2016 24 794 802 26443265 10.1038/ejhg.2015.215 PMC4820094 PubMed DOI
  166. Watson AR Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA) Kidney Int. 2011 80 704 707 21832978 10.1038/ki.2011.209 PubMed DOI

Conditions covered

Autosomal dominant polycystic kidney disease

Reproduced for free educational use under the licence shown above. WhiteCoat Pro is not affiliated with or endorsed by the authors, the publisher or the issuing organisation. Always check the original document for the current version.